2096-P: Real-World Examination of Lorcaserin Treatment in Patients with Type 2 Diabetes, Prediabetes, and Metabolic Syndrome

Volume: 68
Published: Jun 1, 2019
Abstract
Background: Lorcaserin is a serotonin 2C receptor agonist approved in the U.S. as adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in patients with a BMI ≥ 30 or ≥ 27 with at least one weight-related comorbidity. To date, there is limited data on the real-world use of lorcaserin for weight management, including in patients diagnosed with T2DM, prediabetes, and metabolic syndrome. null Methods: A...
Paper Details
Title
2096-P: Real-World Examination of Lorcaserin Treatment in Patients with Type 2 Diabetes, Prediabetes, and Metabolic Syndrome
Published Date
Jun 1, 2019
Journal
Volume
68
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.